NYSEAMERICAN:CCEL

Cryo-Cell International (CCEL) Stock Price, News & Analysis

$7.72
-0.20 (-2.53%)
(As of 04/23/2024 ET)
Today's Range
$7.50
$7.84
50-Day Range
$5.03
$6.14
52-Week Range
$3.67
$8.15
Volume
3,730 shs
Average Volume
12,607 shs
Market Capitalization
$62.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CCEL stock logo

About Cryo-Cell International Stock (NYSEAMERICAN:CCEL)

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

CCEL Stock Price History

CCEL Stock News Headlines

This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Cryo-Cell International, Inc. (CCEL)
Cryo-Cell International Inc.
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
CPS Technologies CEO resigns
Cell Banking Outsourcing Market Outlook by 2031
CCEL Cryo-Cell International, Inc.
See More Headlines
Receive CCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cryo-Cell International and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/15/2024
Today
4/24/2024
Fiscal Year End
11/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:CCEL
Employees
82
Year Founded
N/A

Profitability

Net Income
$-9,520,000.00
Pretax Margin
-43.94%

Debt

Sales & Book Value

Annual Sales
$31.34 million
Cash Flow
$0.69 per share
Book Value
($1.33) per share

Miscellaneous

Free Float
5,263,000
Market Cap
$62.53 million
Optionable
Not Optionable
Beta
0.45
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. David I. PortnoyMr. David I. Portnoy (Age 61)
    Chairman & Co-CEO
    Comp: $1.45M
  • Mr. Mark L. Portnoy (Age 60)
    Co-CEO & Director
    Comp: $990k
  • Ms. Jill M. Taymans (Age 54)
    CFO & VP of Finance
    Comp: $254.77k
  • Mr. Oleg Mikulinsky (Age 51)
    Chief Information Officer
    Comp: $382.77k
  • Dr. Joanne Kurtzberg M.D.
    Medical Director and Member of Medical & Scientific Advisory Board

CCEL Stock Analysis - Frequently Asked Questions

Are investors shorting Cryo-Cell International?

Cryo-Cell International saw a decline in short interest in March. As of March 31st, there was short interest totaling 21,900 shares, a decline of 17.4% from the March 15th total of 26,500 shares. Based on an average daily volume of 9,900 shares, the short-interest ratio is currently 2.2 days. Currently, 0.5% of the company's stock are short sold.
View Cryo-Cell International's Short Interest
.

How were Cryo-Cell International's earnings last quarter?

Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) issued its quarterly earnings results on Monday, April, 15th. The company reported $0.07 earnings per share for the quarter. The company had revenue of $7.85 million for the quarter. Cryo-Cell International had a negative net margin of 31.02% and a negative trailing twelve-month return on equity of 64.31%.

Who are Cryo-Cell International's major shareholders?

Cryo-Cell International's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Massmutual Trust Co. FSB ADV (1.34%) and Rowlandmiller & PARTNERS.ADV (0.17%).
View institutional ownership trends
.

How do I buy shares of Cryo-Cell International?

Shares of CCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:CCEL) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners